LQDA vs. TMDX, BLCO, SLNO, INSP, PRCT, NVST, LIVN, WRBY, NVCR, and LMAT
Should you be buying Liquidia Technologies stock or one of its competitors? The main competitors of Liquidia Technologies include TransMedics Group (TMDX), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.
Liquidia Technologies vs. Its Competitors
Liquidia Technologies (NASDAQ:LQDA) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
64.5% of Liquidia Technologies shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 30.1% of Liquidia Technologies shares are owned by company insiders. Comparatively, 7.0% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
TransMedics Group has higher revenue and earnings than Liquidia Technologies. Liquidia Technologies is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Liquidia Technologies presently has a consensus price target of $26.89, indicating a potential upside of 123.27%. TransMedics Group has a consensus price target of $127.33, indicating a potential upside of 0.61%. Given Liquidia Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Liquidia Technologies is more favorable than TransMedics Group.
In the previous week, TransMedics Group had 3 more articles in the media than Liquidia Technologies. MarketBeat recorded 8 mentions for TransMedics Group and 5 mentions for Liquidia Technologies. TransMedics Group's average media sentiment score of 1.34 beat Liquidia Technologies' score of 0.71 indicating that TransMedics Group is being referred to more favorably in the news media.
Liquidia Technologies has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500.
TransMedics Group has a net margin of 10.03% compared to Liquidia Technologies' net margin of -903.80%. TransMedics Group's return on equity of 21.88% beat Liquidia Technologies' return on equity.
Summary
TransMedics Group beats Liquidia Technologies on 11 of the 16 factors compared between the two stocks.
Get Liquidia Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Liquidia Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:LQDA) was last updated on 7/2/2025 by MarketBeat.com Staff